ML

MoonLake ImmunotherapeuticsNASDAQ MLTX Stock Report

Last reporting period 30 Sep, 2023

Updated 22 Nov, 2024

Last price

Market cap $B

3.412

Middle

Exchange

XNAS - Nasdaq

MLTX Stock Analysis

ML

Uncovered

MoonLake Immunotherapeutics is uncovered by Eyestock quantitative analysis.

Market cap $B

3.412

Dividend yield

Shares outstanding

38.978 B

Website

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

View Section: Eyestock Rating